Breast Cancer Diagnosis clinical trials

Long-term health and fertility study for women with breast cancer

This study follows women with breast cancer and certain lymphomas to understand long-term sexual and reproductive health. It may help researchers better support patients’ body changes and wellness over time during and after treatment.

Nurse Support Program for Triple-Negative Breast Cancer

This study tests a nurse-led coping and support program for people who recently finished treatment for triple-negative breast cancer. The program is designed to help you manage stress and emotional distress after treatment.

Adding immune treatments to improve checkpoint drug response in TNBC

This Phase 2 trial tests strategies meant to “prime” the immune system so that immune checkpoint medicines may work better in people with triple-negative breast cancer that has spread (or can’t be fully cured). You might be considered if your cancer has measurable areas that can be biopsied and you meet specific health and prior-treatment rules.

Atezolizumab plus tivozanib for hard-to-treat “cold” cancers

This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.

Can aromatherapy reduce distress before breast cancer radiotherapy?

This trial tests if inhaling certain scents (aromatherapy) can help calm and reduce distress in breast cancer patients just before their first radiotherapy session.

Study of LNCB74 for advanced solid tumors

This trial tests a new drug called LNCB74 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective.

Liver-directed chemo with standard chemo for breast cancer

This trial tests if giving a high dose of chemotherapy directly into the liver, followed by standard chemotherapy, is safe and works better than standard chemo alone for people with breast cancer that has spread mostly to the liver.

Study of cancer treatment and outcomes during pregnancy

This study looks at pregnant people who were diagnosed with cancer around pregnancy and how care affects the mother, baby, and newborn. It aims to better understand outcomes and treatment patterns during pregnancy.

Blood tests during treatment to track ovarian egg supply

This study measures blood biomarkers to understand how breast cancer treatment affects a person’s future fertility (ovarian reserve). It may help patients learn more about egg supply changes after chemotherapy and hormone-related treatments.

Church-based program to help Korean women get breast screenings

This trial tests a faith-based (church-based) navigation program meant to help Korean women who have not had recent breast cancer screening get a mammogram. It may help by offering support and guidance through church and study staff.

Study how chemotherapy affects brain function in breast cancer

This study looks at changes in thinking and brain function in people with early to locally advanced breast cancer before and during chemotherapy. You may also be offered a brain MRI in a separate optional part of the research to learn more about brain changes.

Better overall care for certain cancer patients

This study looks at how to improve day-to-day support and coordination between cancer doctors and primary care doctors for people with certain early cancers. It may help if you have other ongoing health problems (like diabetes or high blood pressure) or lifestyle factors that need ongoing management during cancer treatment.

Immunotherapy and targeted drugs for advanced triple-negative breast cancer

This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.

Study compares two HER2 breast cancer treatments after surgery

This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.

NEPA for nausea prevention during T-DXd in advanced HER2+ or HER2-low breast cancer

This trial tests whether the anti-nausea combination NEPA (netupitant and palonosetron) can prevent nausea and vomiting caused by the targeted therapy T-DXd in people with advanced HER2-positive or HER2-low breast cancer. It may help you if you are about to start T-DXd for the first time and want to manage treatment side effects.

Tracking cancer recurrence risk after treatment

This study uses advanced blood tests to detect tiny amounts of cancer DNA after you've completed cancer treatment. The goal is to catch any signs of cancer coming back as early as possible, which may help doctors intervene sooner.

Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast Cancer Patients (PhActHealth Study)

Pre-surgery hormone therapy with or without PI3K inhibitor

This trial tests whether giving hormone-blocking treatment before surgery works better when combined with an added targeted drug for certain breast cancers. It may help shrink the tumor and improve outcomes for people whose tumors have specific hormone and genetic features.

Neoadjuvant TQB2102 for HER2-positive breast cancer

This trial tests a new drug called TQB2102 given before surgery for HER2-positive breast cancer. The goal is to see if it can shrink the tumor enough to allow a successful surgery.

New drug combo for HER2-positive breast cancer before surgery

This trial tests a new targeted drug (BL-M07D1) with or without another drug called pertuzumab, compared to a standard chemotherapy plus two targeted drugs, before surgery for HER2-positive breast cancer. The goal is to see if the new combination works better at shrinking tumors before surgery.

Genetics study to find why HER2 breast cancer treatment varies

This study looks at genetic factors to understand why some people’s HER2-positive breast cancer responds better—or has more side effects—after treatment. Your info and possible past treatment history may help researchers improve how HER2 treatment is chosen and managed.

Trastuzumab with chemo for HER2-positive breast cancer

This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.

Testing marker-guided treatment before surgery for HER2-positive breast cancer

This trial studies how well a HER2-focused treatment plan works before surgery (“neoadjuvant” therapy) for operable HER2-positive breast cancer. It also uses tumor tissue tests to find markers that may predict who benefits most.

New drug combo for advanced HER2-positive breast cancer

This trial tests a new drug called IBI354 (an antibody-drug conjugate) given with or without pertuzumab, compared to the standard combination of taxane, trastuzumab, and pertuzumab, for people with HER2-positive breast cancer that has spread and who have not had prior treatment for advanced disease.